# DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

> **NCT02182596** · PHASE1,PHASE2 · COMPLETED · sponsor: **Acute Leukemia French Association** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Mylotarg

## Key facts

- **NCT ID:** NCT02182596
- **Lead sponsor:** Acute Leukemia French Association
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-09
- **Final completion:** 2011-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182596, "DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*